Press Releases

Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual th...
  • 2022-06-22  14:20:57
Shanghai Ruijin Hospital recently announced that it has initiated an investigator-initiated clinical trial (IIT) to evaluate the safety and efficacy of Bofutrelvir administered by inhalation for post-exposure prophylaxis in close contacts of COVID-19 (NCT05415241). It is a single-arm, open-label, m...
  • 2022-06-15  10:45:23
Frontier Biotech (stock code: 688221.SH) announced that the Phase II/III clinical study protocol of FB2001 (generic name: Bofutrelvir) is approved by the Center for Drug Evaluation, NMPA. The study is a worldwide multi-center, randomized, double-blind and placebo-controlled Phase II/III trial to ev...
  • 2022-04-27  10:49:31
On July 15, 2021, The openning ceremony of a new state of the art peptide manufacture facility was held in Jintang, Chengdu. The successful completion of the facility marks the successful industrialization of Aikening® in Jintang.Aiming at intelligent manufacturing, high efficiency and eco syst...
  • 2021-08-31  16:54:43
Nanjing, China, October 28, 2020 -- Frontier Biotechnologies Inc.( Frontier Biotech), a commercial-stage biopharmaceutical company focused on discovering, development, manufacturing, and commercialization of innovative medicines, today announced its completion of the Initial Public Offering (IPO) an...
  • 2020-10-28  09:04:39
July 21, 2021 Nanjing, China. Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global H...
  • 2021-08-30  15:52:59
Frontier Biotech (688221.SH) recently received the Certificate of Registration of Foreign Medicines issued by the Ministry of Health of Ecuador for companys innovative anti-HIV drug AikeningTM (Albuvirtide for injection 160 mg) to be marketed in Ecuador.AlfusidTM is the registered trade mark of Aike...
  • 2021-03-18  19:58:20
Nanjing, China, Nov 7th, 2019 - Frontier Biotechnologies, Inc. (Frontier Biotech) announced that US Food and Drug Administration (USFDA) has granted the Fast Track designation (FTD) to its all-injectable anti-HIV two-drug combination of 3BNC117 and Aikening® for the treatment of multidrug-resis...
  • 2019-11-07  11:15:06
NanjingSep. 26th, 2019 Frontier Biotechnologies (“Frontier Biotech”), a biopharmaceutical company headquartered in China, focusing on innovative drug development for anti-HIV treatment and pain management, and Thermo Fisher Scientific, the world leader in serving science, announced that they have en...
  • 2019-09-29  16:26:53
Keith AlcornPublished: 28 October 2016A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced...
  • 2019-01-25  15:47:42
August 21, 2018 Nanjing, ChinaFrontier Biotech announced today its IND of novel long-acting, all-injectable anti-HIV two drug combo (albuvirtide for injection, ABT and 3BNC117) was allowed by the US FDA on August 14th 2018, and the company will start a phase II clinical trial of the combo therapy in...
  • 2018-08-21  11:00:35

Develop Innovative Therapies to Better Human Lives